On 2026-04-23, the Senate voted on To establish a deficit-neutral reserve fund relating to requiring the Comptroller General of the United States to conduct a study related to economic consequences of private or confidential drug pricing agreements struck by any Federal department, agency, or office with any pharmaceutical manufacturer.. The recorded result was Amendment Rejected, with 48 Yea and 50 Nay votes. See how each senator voted below.